By Yin Wilczek
Sept. 2 — The U.S. Court of Appeals for the Ninth Circuit Sept. 2 revived a shareholder derivative lawsuit alleging that Allergan Inc.'s current and former directors were liable for state and federal violations and breached their fiduciary duties over Botox marketing practices.
Reversing the U.S. District Court for the Central District of California and remanding, the Ninth Circuit ruled that the plaintiffs were excused from making a presuit demand on Allergan's board to bring the derivative claims in the company's name.
Applying Delaware law, the court found that the plaintiffs' factual allegations and, “more important, the reasonable inferences” that must be drawn in the plaintiffs' favor adequately show that the board either did nothing despite knowing of wrongdoing or “knowingly adopted a business plan premised on illegal conduct.”
“In either case, Allergan's directors violated their duty of loyalty and would face a substantial likelihood of liability; in the latter case, they would also have forfeited the protection of the business judgment rule,” the court concluded in an opinion by Judge Stephen Reinhardt.
Reinhardt also wrote a separate special concurrence, opining that in demand futility cases “in which the standard of review is determinative of the outcome,” the proper standard of review should be de novo.
In September 2010, Allergan pleaded guilty to criminal charges for Botox misbranding and agreed to pay a total of $600 million in criminal and civil fines. Several Allergan stockholders filed derivative lawsuits, including the Louisiana Municipal Police Employees' Retirement System in Delaware and other stockholders in California federal court.
In January 2012, the U.S. District Court for the Central District of California dismissed the derivative suit for failure to adequately allege demand futility.
In a case involving almost identical issues, the Delaware Court of Chancery in June 2012 went the opposite direction, finding that the plaintiffs had shown demand futility. The state supreme court subsequently reversed the chancery court solely on the grounds that the Delaware plaintiffs were collaterally estopped from pursuing their claims in chancery court due to the earlier-filed dismissal of the complaint by the district court.
The Ninth Circuit said it agreed with the chancery court's decision that demand was excused. The plaintiffs' allegations—including that the illegal off-label promotion of Botox persisted for more than a decade and involved several Allergan divisions—suggested a “combination of widespread and enduring illegality” that “strongly supports an inference of Board knowledge and intentional disregard,” the court wrote.
The Ninth Circuit also found that the district court committed a number of errors and thus abused its discretion. Among other problems, the district court considered the plaintiffs' factual allegations in isolation rather than in combination.
In addition, the lower court “repeatedly drew inferences in the Board's favor,” crediting the company's reasonable interpretations of the factual allegations over the plaintiff's reasonable interpretations of the same allegations, the appeals court wrote. “Finally, the district court essentially insisted on a smoking gun of Board knowledge, even though precedent holds that plaintiffs can show demand futility by alleging particular facts that support an inference of conscious inaction.”
The plaintiffs were represented by Joseph D. Daley, Robbins Geller Rudman & Dowd LLP, San Diego.
Allergan's current and former directors were represented by Mark Perry, Gibson Dunn & Crutcher LLP, Washington.
To contact the reporter on this story: Yin Wilczek in Washington at email@example.com
To contact the editor responsible for this story: Phyllis Diamond at firstname.lastname@example.org
The decision is available at http://www.bloomberglaw.com/public/document/Willa_Rosenbloom_et_al_v_David_Pyott_et_al_Docket_No_1255516_9th_.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).